author-photo

Charles M. Farber

Memorial Hospital of South Bend

60

Papers

1187

Citations

Citation Trend

Filter By

Papers (50) Sort By

Journal Conference Others

456 A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

2018 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (12)
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study

2018 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry

2017 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (11)
Variation in health-related quality of life (HRQOL) by line of therapy, age, and gender among patients with chronic lymphocytic leukemia.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Treatment of Peripheral T-Cell Lymphoma in Community Settings

2017 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (4)
An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

2017 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.

2017 Blood Advances
Show All
- Source
- Cite
- Save
Citations (7)